Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Theodore Stewart Gourdin, Viktor Grünwald(Deutsche Schmerzgesellschaft), Toshio Takagi(Tokyo Women's Medical University), Sung‐Hoo Hong(Seoul National University Bundang Hospital), Bohuslav Melichar(Palacký University Olomouc), Shirley Wong(Western Hospital), Sergei Tjulandin, Chinyere E. Okpara(Eisai (United Kingdom)), Luke T. Nordquist(Virginia Cancer Institute), Sandhya Srinivas(Stanford Medicine), David R. Spigel(Sarah Cannon), Jeffrey C. Goh(Royal Brisbane and Women's Hospital), Camillo Porta(University of Pavia), B. Yа. Alekseev(P.A. Hertzen Moscow Oncology Research Institute), Sun Young Rha(Yonsei University), Brendan D. Curti(Providence Portland Medical Center), Anna Alyasova, Aly‐Khan A. Lalani(Juravinski Cancer Centre), Pablo Maroto(Hospital de Sant Pau), Howard Gurney(Radboud University Nijmegen), Eric Winquist(Western University), Subramanya Rao, Jaime R. Merchan(Sylvester Comprehensive Cancer Center), Joseph E. Burgents(Merck & Co., Inc., Rahway, NJ, USA (United States)), Toni K. Choueiri(Harvard University), Karla Rodriguez-Lopez(Merck & Co., Inc., Rahway, NJ, USA (United States)), Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Manuela Schmidinger(Medical University of Vienna), Jodi A. McKenzie(Peter MacCallum Cancer Centre), Teresa Alonso‐Gordoa(Instituto Cajal), Saby George(Roswell Park Comprehensive Cancer Center), Jens Bedke, Evgeny Kopyltsov(Inserm), Vadim Kozlov(State Healthcare Institution "Regional Clinical Oncological Dispensary"), Thomas Powles(Queen Mary University of London), Miso Kim(Seoul National University Hospital), Thomas E. Hutson(Texas Tech University), Andrew Pippas(Piedmont HealthCare), María José Méndez(Hospital Universitario Reina Sofía), Cixin He(Eisai (United Kingdom)), Elisabeth I. Heath(The Barbara Ann Karmanos Cancer Institute), Avivit Peer(Technion – Israel Institute of Technology), Masatoshi Eto(Kyushu University)
Cited by 170
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k